期刊
STEM CELL REPORTS
卷 12, 期 5, 页码 1041-1055出版社
CELL PRESS
DOI: 10.1016/j.stemcr.2019.04.003
关键词
-
资金
- NIH [R01 HL107307, R01 HL140595, RO1 HL135163, PO1 HL108793, R01 HL126732, HL132156, HL146461]
- DFG [BE443/4-1, BE443/6-1]
- Loewe
- UKGM
- VA-CDA [1IK2BX002401-01A2]
- VA Merit [I01 BX003471]
- Pulmonary Fibrosis Foundation Albert Rose established investigator award
Idiopathic pulmonary fibrosis is a common form of interstitial lung disease resulting in alveolar remodeling and progressive loss of pulmonary function because of chronic alveolar injury and failure to regenerate the respiratory epithelium. Histologically, fibrotic lesions and honeycomb structures expressing atypical proximal airway epithelial markers replace alveolar structures, the latter normally lined by alveolar type 1 (AT1) and AT2 cells. Bronchial epithelial stem cells (BESCs) can give rise to AT2 and AT1 cells or honeycomb cysts following bleomycin-mediated lung injury. However, little is known about what controls this binary decision or whether this decision can be reversed. Here we report that inactivation of Fgfr2b in BESCs impairs their contribution to both alveolar epithelial regeneration and honeycomb cysts after bleomycin injury. By contrast overexpression of Fgf10 in BESCs enhances fibrosis resolution by favoring the more desirable outcome of alveolar epithelial regeneration over the development of pathologic honeycomb cysts.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据